The partner that transforms specialized portfolios into institutional access
Lanco Medical Group connects manufacturers and specialized portfolios with institutional channels, tenders, and regional pharmaceutical execution in
Central America and the Caribbean
Active Countries
Units 2025
Institutional Channel
Years in Operation
Regional growth requires more than distribution
Most distributors compete in saturated markets, without access institutional nor specialized regulatory infrastructure
Low-margin portfolios — Many regional distributors continue to compete only in traditional generics, where the margins and growth are increasingly limited.
Institutional tenders out of reach — CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa concentrate a large part of the regional market and require experience operational, institutional relationships, and capacity to execution.
RTCA regulatory complexity — Registering products in multiple markets requires specialized teams, regulatory monitoring, and regional operational structure.
Access to specialized molecules Biosimilars, biologics, anticoagulants, oncology, neurology and next-generation therapies with implementation active institutional
Regional institutional infrastructure — Active experience in institutional access, management of key accounts and specialized pharmaceutical execution.
Specialized regulatory management
RTCA coordination, maintenance of active records and regulatory support for generics, biosimilars, and specialized therapies.
Specialized portfolio by therapeutic area
Anticoagulants and Hematology
Leadership in hemophilia treatments in Costa Rica and active institutional access in CSS, CCSS, and IGSS.
Oncology and Biosimilars
Biosimilars from international manufacturers with experience in RTCA regulatory management and institutional bidding.
Cardiovascular
Portfolio with active presence in public and private channels throughout the region.
Diabetes and Metabolism
Priority access to institutional programs for chronic diseases in strategic markets.
Neurology
Experience in hospital protocols, chronic management, and specialized therapies.
High Specialty and Biologicals
Biologics and specialized therapies with regulatory support, qualified distribution, and clinical follow-up.
Cases, results, and regional recognition
More than regional presence, we build sustained institutional access in strategic markets of Central America and the Caribbean
Years in Operation
Active Countries
Units 2025
Institutional Channel
Largest institutional contract awarded in our therapeutic area — CCSS Costa Rica.
Leadership in hemophilia treatment in Costa Rica.
Active regional operation in 6 markets institutional
Distributor of the Year — U.S.
Happy Workers Award — Panama.
Entrepreneur of the Year (USA)
Active institutional presence in
Central America and the Caribbean
Guatemala
IGSS — Guatemalan Social Security Institute
Sustained growth in specialized portfolios.
Honduras
IHSS — Honduran Social Security Institute
Active institutional access and specialized commercial force.
Dominican Republic
SeNaSa — National Health Insurance
Institutional expansion in one of the Caribbean markets with the greatest potential.
El Salvador
El Salvador
ISSS — Salvadoran Social Security Institute
Institutional coverage and active private channel.
Costa Rica
CCSS — Costa Rican Social Security Fund
Our most relevant institutional contract and leadership in hemophilia.
Panama
CSS — Social Security Fund
Regional operational hub with public and private coverage
We are Lanco Medical Group
For more than 12 years, we have built institutional relationships, regulatory infrastructure, and specialized execution in Central America and the Caribbean.
Lanco Medical Group operates as a specialized regional platform for high-value pharmaceutical portfolios. high-value pharmaceuticals.
We do not compete as a traditional generic distributor. We integrate institutional access, support regulatory, specialized distribution, and regional commercial execution.
144 million units distributed in 2025 represent patients attended to, active institutions, and real execution capacity.
Part of the LMG Bio Lifesciences ecosystem, connecting global pharmaceutical manufacturers with Latin America.
A regional infrastructure
Two models of alliance
We work with regional distributors and pharmaceutical manufacturers international under models of collaboration adapted to each operational structure
Discover:
Which molecules are compatible with your current network.
How does joint institutional access work?
What RTCA regulatory support is included.
What commercial structure allows competition in channels
institutional.
No generic proposals. No commitments before understanding their operation.
I'm an international manufacturer
We analyze:
Regional distribution and access capacity institutional.
Active RTCA records and available regulatory support.
Institutional history and bidding experience.
Operational structure, timelines, and needs regulatory for your molecule.
This isn't a commercial pitch. It's a strategic capabilities assessment.
I want more information
Regional pharmaceutical execution
Real institutional access
Lanco Medical Group · info@lancomedicalgroup.com · www.lancomedicalgroup.com
Panamá · Costa Rica · Guatemala · Honduras · El Salvador · República Dominicana
República Dominicana
Guatemala
Panamá
El Salvador
Honduras
Costa Rica
México
Guatemala
República Dominicana
Panamá
El Salvador
Honduras
Costa Rica
México
Guatemala
República Dominicana
Lanco Medical Group © 2026 – All rights reserved.
